News

GECI INTERNATIONAL CONFIRMS ITS RETURN TO GROWTH, WITH 2021-22 FULL-YEAR REVENUES UP 7.6%

GECI International, the Digital and Technology specialist, returned to growth in FY 2021-22, securing

Significant points:

• Printing activity attained its highest annual level on record, driven by sustained demand. Inflationary pressures however impact margins.
• Hardware activity posts moderate

Montigny Le Bretonneux, May 2, 2022

Erratum on Q1 2022 revenue

In the press release published Friday, April 29 on the 2021 results, an error slipped into the paragraph on the activity of the 1st

Montigny Le Bretonneux, April 29, 2022

2021 RESULTS

• A 2021 financial year characterized by preparing for future growth
• Significant increase in activity in the 1^st quarter of 2022, which benefits

2021 annual results: strong increase in the value of Transition Evergreen assets, demonstrating the appeal of holdings and their growth performance

FY 2021 net income: €30.9m

Restated NAV^[1] of

LIMONEST, 28 APRIL 2022, 5.45 PM

• Q4 REVENUES OF €160.1M, FOLLOWING A RETURN TO A NORMAL RATE OF CONSUMPTION
• FULL-YEAR BTOB REVENUES UP 4.8% TO €194.7M
• OBJECTIVE OF STRENGTHENING LDLC'S BRAND

Paris, April 28, 2022,

Netgem announces that it has made available to the public and filed with the Autorité des Marchés Financiers its annual financial report as of December 31, 2021.

The annual

Montigny Le Bretonneux, April 27, 2022

DOLFINES RAISES €200,000 IN THE FORM OF BONDS CONVERTIBLE INTO SHARES WITH SHARE PURCHASE WARRANTS

DOLFINES (the "Company") recalls having signed, on June 15

Lyon, France – 25 April 2022 – 7:00 am CEST –Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating

The Group announces its first "Play to Earn" type game whose economy is centered on the new $OLYMP token and NFTs that can be used in the game.

With the acquisition of a 37.5% stake in OLYMPUS GAME

Paris, April,19^th, 2022

AgroGeneration, a Ukraine based grain and oilseed producer, provides an update on the current company's performance and gives an overview of the impacts of the Russian

2021 Results

Growth of more than 30% in the number of subscribers to 363.000 at year-end

Operational performance up sharply: EBITDA of €4.3m (x 4.8)

Increase in net cash to €4.0 million (+€2.2

 Press release – March 30, 2022

Progress report at the end of March 2022

DOLFINES, an independent specialist in engineering and services in the renewable and conventional energy industry, offers a

PRISMAFLEX INTERNATIONAL, listed on the Euronext Growth^TH Paris (Code ISIN FR0004044600), confirms its eligibility for the small and mid-caps PEA-PME equity savings vehicle, in accordance with the

_ EBITDA: €9.4m (up 23%)

EBIT: €4.9m (up 22%)

NET INCOME: €4.1m (up 25%)

_ STREAMWIDE (FR0010528059 – ALSTW – eligible for the French

Paris, March 3^rd, 2022

AgroGeneration, a Ukraine based grain and oilseed producer, considering the political situation in Ukraine and its impact on the work of its teams, suffered of difficulties

PRESS RELEASE La Garde (France), March 1^st 2022

CIOA announces a 165 million euro financing to accelerate its development

CIOA Group, an engineering and development company, announces a €165m

Paris, February 28^th, 2022

AgroGeneration, a Ukraine based grain and oilseed producer, suspended all activities (spring sowing campaign preparation) of the Group starting from February 24^th, the

• · New milestone for NeuroLead, the active agent screening platform
• · New publications in scientific journals
• · Start of Phase I/II clinical trial for Batten disease

Lyon, 28 February 2022

LIMONEST, 24 FEBRUARY 2022, 6.00 PM

• SHARP DECLINE IN BUSINESS IN FEBRUARY
• ADJUSTMENT OF ANNUAL TARGETS FOR 2021-2022: REVENUE OF AROUND €680M AND EBITDA OF AROUND €55M
• SOLID BUSINESS

_ STREAMWIDE (FR0010528059 – ALSTW – eligible for the French PEA-PME), the

_ STREAMWIDE (FR0010528059 - ALSTW - eligible for French PEA-PME), the expert in

Lyon, France – Austin, TX, USA - 3 February 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates

LIMONEST, 27 JANUARY 2022, 5.45 PM

• 9-MONTH REVENUES DIP -3.2% TO €524.8M
• STRONG MOMENTUM IN BTOB AND STORE SALES
• Q3 REVENUES OF €191.4M IMPACTED BY SHORTAGE OF GRAPHICS CARDS

Olivier de la

 Press release – January 26, 2022

DOLFINES CONTINUES TO STRENGTHEN ITS TEAMS TO SUPPORT ITS DEVELOPMENT

DOLFINES announces several appointments to strengthen its development capacities on its two